Drawing for Serial No. 98693417

USPTO serial 98693417

Serial No. 98693417

Reviewed by CopyMark Law Group

Reg. 7972663Status 700Registered
Filing date
Status date
Registration date
Oct 7, 2025
Examiner
CHUO, EMILY M
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with Serial No. 98693417?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Anthony E. Bennett

Anthony E. Bennett Hoffmann & Baron, LLP6900 Jericho TurnpikeSyosset, NY 11791-4407United States

Goods and services

ClassDescriptionStatusFirst use
005Adhesive patches for administering by cutaneous or epicutaneous means of powdered medical or pharmaceutical substances for human purposes for the treatment of allergies; transdermal or epicutaneous patch containing a preparation in powder form for medical use for treating allergies; occlusive patch for cutaneous absorption of a powdered medical substances for the treatment of allergies; all of the aforesaid goods being for human use only.ACTIVE—
010Medical instruments, apparatus and devices for the cutaneous or patch-based administration of medical or cosmetic substances in powder form for human beings for allergy treatment; Medical instrument using the electrostatic properties of a biocompatible medium for the treatment of allergies; all of the aforesaid goods being for human use only.ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 7, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Oct 7, 2025R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Aug 19, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 19, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 13, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 11, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 9, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 9, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 3, 2025ALIEASSIGNED TO LIE—
Jun 20, 2025ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Feb 28, 2025GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Feb 28, 2025GNSLLETTER OF SUSPENSION E-MAILED—
Feb 28, 2025CNSLSUSPENSION LETTER WRITTEN—
Feb 28, 2025XAECEXAMINER'S AMENDMENT ENTERED—
Feb 28, 2025GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Feb 28, 2025GNEAEXAMINERS AMENDMENT E-MAILED—
Feb 28, 2025CNEAEXAMINERS AMENDMENT -WRITTEN—
Feb 26, 2025DOCKASSIGNED TO EXAMINER—
Feb 25, 2025MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Feb 25, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 12, 2024NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance